1. Precise epidermal delivery

2. Best-in-Class   Laser-Assisted   Epidermal Drug Delivery   EPIDRUG™ & EPIMMUN™

3. Company profile Location Ruggell, Liechtenstein Foundation 2005 Dec.
Key assets - proprietary technology in epidermal delivery of immunogens and drugs - portfolio of granted patents and patent applications
- EPIMMUN™: promising pre- clinical results for delivery of variety of immunogens
- EPIDRUG™: clinical proof of concept for several drugs
Investors Private investors, VC company

4. Pantec’s device – P.L.E.A.S.E. Professional
P.L.E.A.S.E. = Precise Laser EpidermAl System
The only existing Ablative Laser Class 1
Full delegation - to be used by non-doctoral staff
No safety precautions required
User-friendly interface for easy programming
Small and mobile for easy use
Precise and painless delivery
Patent protected
Medical CE marked

5. Applications– EPIDRUG™ & EPIMMUN™
EPIDRUG™ and EPIMMUN™ allows for optimal, dose-controlled delivery of various drug and immunogen substances into targeted skin layers offering an optimal safety profile and in case of EPIMMUN™ inducing an active immune-response and triggering a laser adjuvant effect. 5

6. EPIMMUN™ and EPIDRUG™ Process
Precise and reproducible formation of micropores in desired skin layer
Topical administration of substance
Efficient delivery of substance through micropores and uptake relevant immune cells or receptors

7. Laser-assisted generation of micropores – the basis of the P. L. E. A
Laser-assisted generation of micropores – the basis of the P.L.E.A.S.E. platform
We love micro-Pores!

8. Precise Laser EpidermAl SystEm
EPIMMUN™ and EPIDRUG ™ allow for precise, dose-controlled delivery of various substances into targeted skin layers, offering an optimal safety profile.
EPIMMUNTM
EPIDRUG™
Precise epidermal delivery +
Immune stimulant effect; laser adjuvant effect
Precise epidermal delivery
P.L.E.A.S.E.
Precise Laser EpidermAl SystEm

9. Precise micropore depth - delivery to target skin layers9

10. Key advantages of EPIMMUN™ and EPIDRUG™
Easy to use, needle-less, painless, well-tolerated
Reproducible formation of micropores
Precise depth
Desired skin layers
Induction of strong immune response (EPIMMUN™ only)
Precise immunogen delivery to target immune cells
Immune-stimulant effect
200 mm
60 mm

11. Market and Fields of Application
Oncology active Immunotherapy
WW sales in 2014 of $ 41 billion1
Cancer immunotherapy is „ breakthrough treatment of the year 2013“
Checkpoint inhibitors and their combination with cancer active immunotherapies will substantially contribute to expected growth of the market
High medical need for effective immunogen delivery to target immune cells
Preventive and therapeutic vaccines
WW sales of $ 33 billion in 2014 expected to grow to $56 billion in 20192
Needle-less delivery systems are highly needed, particularly in the developing world
Allergy immunotherapy
WW sales of $ 1,1 billion in 20143
Highly underserved market – only 2% of allergic patents are currently treated because of cumbersome treatment schedules (>50 injections) over long period (>3 years)
Autoimmune disease drugs
WW sales expected at $ 61 billion in 20174
Unmet medical need for local targeted delivery (reduce side effects of systemic drug administration) Combined market potential > $100 billion
1 Global & USA Cancer Immunotherapy Market Analysis to 2020
2 Markets and Markets 2015, „Vaccine market by technology – Forecast to 2019
3 ALK, Annual Report 2014
4 GBI Research, Autoimmune Disorders Therapeutics Market to 2017

12. Business Model
Formation of partnerships with biotech and pharmaceutical companies for commercialization of combination products using EPIDRUG™ or EPIMMUNTM together with their proprietary drug or vaccine formulations
To achieve this objective, Pantec
will generate broad database of preclinical and clinical data with EPIDRUG™ and EPIMMUNTM in wide variety of indications in collaboration with (existing and newly formed) research partnerships with leading academic institutions and biotech companies
will use this database to convince pharma companies to combine their substances with EPIDRUG™ and EPIMMUNTM
will enter into licensing agreements with pharma partners in return for upfront and milestone fees as well as royalties

13. Revenue Generation Sales of devices and consumables Licensing revenues
Short Term: Laser devices (and consumables) on rental or purchase basis for research partners
Mid Term: Sales of laser devices and consumables to clinical trial centers and pharma companies conducting studies with partnered products
Cumulative sales revenues of ~ € 1,7 million projected until (2015: ~ € )
Long Term: After launch of partnered product(s) (first launch expected in 2019) substantial increase in sales of laser devices and consumables to end users (physicians)
Licensing revenues
Upfront, Milestone and Royalty payments from pharma partners
Pantec has already signed three such licensing agreements with pharma and biotech companies

14. Financials – Financing Round
Financing Volume: € 4 Million
Funding reach: end 2018
Use of Proceeds:
Business development and marketing/sales activities to leading scientific research institutions and biotech companies
Support of research institutions to generate strong EPIDRUG™/EPIMMUNTM preclinical/clinical data base
Business development for further pharma partnerships
Engineering and design of next generation laser device
Maintenance and Extension of IP portfolio
Key milestones
Successful clinical study as part of existing EPIDRUG™ Pharma collaborations mid of 2016
First clinical data with EPIMMUNTM by end of 2016
Pharma partnership for EPIMMUNTM in 2017
Operational profitability in 2019
Exit potential – As a profitable Medtech company with significant growth potential, Pantec
would be an attractive M&A partner for Medtech and pharma companies
would be an attractive investment case to go public

15. Management Team Reinhard Braun, Co-Founder, President and CEO
Founder, President and CEO of Pantec Engineering AG
Engineering Degree in Electronics
Christof Böhler, PhD, Co-Founder, Exec. Director Business Development
CEO at Pantec Biosolutions from 2006 to 2014
PhD in Chemistry and executive degree in International Management
Elmira Lechat, MD, MBA, Medical Director
Clinical Services Supervisor/Medical Scientific Expert at Medtronic
Assistant at European Respiratory Society
Martin Steiner, PhD, MBA, Business Development EPIMMUNTM
Consultant to biotechnology companies
Founder and CEO of two biotechnology companies
PhD in Microbiology and Genetics and MBA
Tobias Bächle, Sales Director
Senior Regional Sales Manager at Bio Separations GmbH and Macherey-Nagel AG
Engineering Degree in Chemistry

16. Key achievements to date
Laser platform developed at high quality standards
P.L.E.A.S.E. laser platform developed, manufactured and medical CE-marked
Established quality management system, ISO certification
Pharma collaborations in place
Collaborations with Takeda, Ratiopharm and Oncosynergy (Biotech) actively running
First-mover and pioneer in epidermal drug delivery for dermatology and immunotherapy
Strong IP position established
Portfolio of patents granted or filed to protect laser device, as well as EPIDRUG™ and EPIMMUN™
Profound technological and application know-how
Promising preclinical data
EPIMMUN™ concept successfully demonstrated in several animal studies
Activation of relevant immune cells and induction of strong immune response by EPIMMUNTM
Clinical experience
Completed clinical studies EPIDRUG™ prove safe, well-tolerated and reproducible laser microporation
Ongoing clinical project with Takeda Pharmaceuticals
Strong scientific network
Collaborations with leading research groups in different fields of immunotherapy established
Several devices sold or rented to academic institutions and biotech companies

17. Investment Considerations
Proprietary, widely-applicable platform technology
EPIDRUG™ and EPIMMUN™ are pre-clinically and clinically tested with different substances for several different indications
Focus on rapidly –growing immunotherapy market
Pantec is a leading first-mover and pioneer with proprietary technology and know-how
Pantec has extensive network of leading scientific research groups and key opinion leaders
Immunotherapy and vaccine market currently more than 75 billion
Management team with extensive know-how and experience
Multi-year experience in various senior management roles with biotechnology, pharmaceutical and medical technology companies
Financially attractive, low-risk investment
Low technology risk – clinical experience shows excellent safety profile
Existing partnerships with pharma and biotechnology company
Platform applicable to a wide range of indications with large market potential
Attractive Exit potential
Early break even (i.e. before partnered products enter market)
Attractive M&A partner or IPO candidate